Gefitinib is a targeted therapy used for the treatment of non-small cell lung cancer (NSCLC). It belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, which work by blocking the signals that promote cancer cell growth. Gefitinib is particularly effective in patients with specific EGFR mutations, helping to slow disease progression and improve survival rates.
India has emerged as a major producer of high-quality, cost-effective cancer medications, with several Gefitinib tablet manufacturer in India supplying the drug to domestic and international markets. These manufacturers adhere to strict regulatory standards such as WHO-GMP, USFDA, and EU-GMP to ensure the safety, efficacy, and consistency of Gefitinib production.
Indian pharmaceutical companies play a crucial role in making Gefitinib accessible to cancer patients worldwide. By offering high-quality generic alternatives at competitive prices, Indian Gefitinib tablet manufacturers help improve treatment affordability without compromising effectiveness. For hospitals, distributors, and healthcare providers, sourcing from trusted Indian manufacturers ensures a steady supply of this essential cancer therapy.